DGAP-News

MOLOGEN AG: Preparation and launch of new studies characterized the first half-year 2014 - Seite 2

particular, data were presented on long-term treated patients, some of whom
still had no cancer progression for more than 32 - 40 months. Similarly,
the final data for the phase I/II ASET renal cancer study with the cancer
immunotherapy MGN1601 were presented. The study reported promising results
for the overall survival in addition to the excellent safety and
tolerability of the compound.

"Our cancer immunotherapy MGN1703 is now right at the start of the pivotal
phase III IMPALA study. We are one of the few German biotech companies to
have brought a drug into a pivotal study which was self-developed in-house
and financed exclusively by our shareholders. The feedback from experts on
our research results, the leading oncology experts who support the IMPALA
study as investigators, and the broad application of the product - all
confirm the blockbuster potential of MGN1703", said Dr. Matthias Schroff,
Chairman of the Executive Board of MOLOGEN AG.

Expenses for research and development (R&D) for the first half of 2014
increased to 5.9 million euros and therefore exceeded the value in the same
period last year by 3.1 million euros. Decisive factors were mainly the
increased material requirements and a higher number of employees in
connection with the preparation and initiation of new clinical studies. The
net loss for the first half of 2014 amounted to 7.9 million euros, an
increase of 3.6 million euros compared to the previous year.

A successful capital increase performed in February led to an increase in
available cash and cash equivalents for MOLOGEN AG compared to the first
half of 2013. The cash and cash equivalents as of June 30, 2014, amounted
to 22.9 million euros and allow for continued solid financing of the
company's current operations.

MOLOGEN confirmed its outlook for 2014 and expects a net loss significantly
higher than that of the same period last year. The extensive program of
studies leads to higher R&D expenses, which will be reflected accordingly
in the annual results.

The relevant documents on the completed first half 2014 are available on
the website of MOLOGEN AG via www.mologen.com/en/investor-relations.

About MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and
clinical development of cancer immune therapies and DNA vaccines against
infectious diseases.

The cancer immune therapy MGN1703 is the company's lead product and
best-in-class TLR-9 agonist. It is currently developed for first-line
maintenance treatment of colorectal cancer (pivotal randomized trial) and